Regeneron Reports Fourth Quarter and Full Year 2015 Financial and Operating Results

TARRYTOWN, N.Y.,Feb. 9, 2016/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the fourth quarter and full year 2015 and provided an update on development programs.

($ in millions, except per share data)

EYLEA U.S. net product sales

$

746

$

518

44

%

$

2,676

$

1,736

54

%

Total revenues

$

1,098

$

802

37

%

$

4,104

$

2,820

46

%

Non-GAAP net income(2)

$

327

$

328

—

%

$

1,404

$

1,175

19

%

Non-GAAP net income per share - diluted(2)

$

2.83

$

2.79

1

%

$

12.07

$

10.00

21

%

GAAP net income

$

155

$

90

72

%

$

636

$

338

88

%

GAAP net income per share - diluted

$

1.34

$

0.78

72

%

$

5.52

$

2.98

85

%

*See note (4) below for an explanation of revisions made to certain amounts previously reported for the three months and year ended December 31, 2014.

"Regeneron had a successful 2015, with strong growth in EYLEA sales for retinal diseases, the approval of Praluent for hypercholesterolemia, and important advances across all stages of our pipeline," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "In 2016, we look forward to driving increased physician education, patient access, and reimbursement for Praluent inthe United Statesand to launching this important medicine in other countries around the world.  We also anticipate significant pipeline progress including the U.S. FDA action on the sarilumab application for rheumatoid arthritis, the Phase 3 results and potential U.S. regulatory submission for dupilumab in atopic dermatitis, and the continued progress of our development programs for retinal diseases, asthma, pain, infectious diseases, and cancer.  Realizing these important product and pipeline opportunities will require significant investments, which are essential to support our long-term growth and success."

• In the fourth quarter of 2015, net sales of EYLEA inthe United Statesincreased 44% to$746 millionfrom$518 millionin the fourth quarter of 2014.  For the full year of 2015, net sales of EYLEA inthe United Statesincreased 54% to$2.676 billionfrom$1.736 billionfor the full year 2014.  Overall distributor inventory levels remained within the Company's one- to two-week targeted range.

• Bayer HealthCare commercializes EYLEA outside the United States.  In the fourth quarter of 2015, net sales of EYLEA outside ofthe United States(1)were$413 million, compared to$297 millionin the fourth quarter of 2014.  In the fourth quarter of 2015, Regeneron recognized$140 millionfrom its share of net profit from EYLEA sales outsidethe United States, compared to$88 millionin the fourth quarter of 2014.  For the full year of 2015, net sales of EYLEA outside ofthe United States(1)were$1.413 billion, compared to$1.039 billionfor the full year 2014.  For the full year of 2015, Regeneron recognized$467 millionfrom its share of net profit from EYLEA sales outsidethe United States, compared to$301 millionfor the full year 2014.

• InOctober 2015, the European Commission granted marketing authorization of EYLEA for the treatment of visual impairment due to myopic choroidal neovascularization.

• In the fourth quarter of 2015, net sales of Praluent were$7 million.  For the full year of 2015, net sales of Praluent were$11 million.  Product sales for Praluent are recorded by Sanofi, and the Company shares in any profits or losses from the commercialization of Praluent.  Praluent was launched inthe United Statesin the third quarter of 2015 and in certain countries in the European Union in the fourth quarter of 2015.

• The Phase 3 ODYSSEY OUTCOMES trial completed enrollment during the fourth quarter of 2015.

Regeneron has thirteen product candidates in clinical development.  These consist of EYLEA and twelve fully human monoclonal antibodies generated using the Company'sVelocImmune®technology, including four in collaboration with Sanofi.  In addition to EYLEA and Praluent, highlights from the antibody pipeline include:

Sarilumabis the Company's antibody targeting IL-6R for rheumatoid arthritis.  InDecember 2015, the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for sarilumab, with a target action date ofOctober 30, 2016. Sarilumab is currently being studied in the global Phase 3 SARIL-RA program

Dupilumab, the Company's antibody that blocks signaling of IL-4 and IL-13, is currently being studied in atopic dermatitis, asthma, nasal polyps, and eosinophilic esophagitis.

• Multiple Phase 3 studies of dupilumab in atopic dermatitis are currently underway.  Phase 3 pivotal trials in atopic dermatitis are fully enrolled.

• A Phase 3 pivotal study of dupilumab in patients with uncontrolled persistent asthma continues to enroll patients.

Fasinumabis an antibody targeting Nerve Growth Factor (NGF).  A sixteen-week Phase 2b/3 clinical trial for pain due to osteoarthritis has completed enrollment.  The FDA has confirmed that the Company may proceed with studies of longer than sixteen-week duration.

REGN2222, an antibody targeting the respiratory syncytial virus (RSV), is in Phase 3 clinical development.  InOctober 2015, the FDA granted Fast Track designation to REGN2222 for the prevention of serious lower respiratory tract disease caused by RSV.

EYLEA

-

Initiate Phase 3 study for the treatment of diabetic retinopathy in patients without diabetic macular edema (DME)

REGN2176-3 (PDGFR-betaAntibody co-formulated withaflibercept)

-

Report results from Phase 2 study

Nesvacumab/aflibercept(Ang2 Antibody co-formulatedwith aflibercept)

-

Initiate Phase 2 study

Praluent

-

Independent Data Monitoring Committee (IDMC) interim analyses of ODYSSEY OUTCOMES trial

-

Ongoing launch in the United States as well as in additional territories outside the United States

Sarilumab (IL-6R Antibody)

-

Regulatory decision in the United States

-

File for regulatory approvals outside the United States

-

Report results from Phase 3 SARIL-RA-MONARCH trial evaluating sarilumab versus adalimumab in monotherapy

Dupilumab (IL-4R Antibody)

-

Report results from Phase 3 atopic dermatitis pivotal trials

-

Complete rolling BLA submission for atopic dermatitis in the United States

Fasinumab (NGF Antibody)

-

Report results from Phase 2b/3 study in osteoarthritis

-

Initiate longer duration (greater than 16 weeks) Phase 3 trial

Immuno-oncology (PD-1 Antibodyand bi-specific antibody against CD20 and CD3)

-

Report data from Phase 1 studies in patients with cancer

Product Revenues:Net product sales were$750 millionin the fourth quarter and$2.689 billionfor the full year 2015, compared to$522 millionin the fourth quarter and$1.751 billionfor the full year 2014.  EYLEA net product sales inthe United Stateswere$746 millionin the fourth quarter and$2.676 billionfor the full year 2015, compared to$518 millionin the fourth quarter and$1.736 billionfor the full year 2014.

Total Revenues:Total revenues, which include product revenues described above, increased by 37% to$1.098 billionin the fourth quarter of 2015, compared to$802 millionin the fourth quarter of 2014.  Total revenues also include collaboration revenues of$330 millionin the fourth quarter of 2015, compared to$272 millionin the fourth quarter of 2014.  Full year 2015 total revenues increased by 46% to$4.104 billion, compared to$2.820 billionfor the full year 2014, and included collaboration revenues of$1.339 billionfor the full year 2015, compared to$1.037 billionfor the full year 2014.  Collaboration revenues in the fourth quarter and full year 2015 increased primarily due to higher reimbursement of the Company's research and development expenses under its antibody collaboration with Sanofi, an increase in the Company's net profit from commercialization of EYLEA outsidethe United States, and reimbursement of the Company's research and development expenses and amortization of up-front payments received in connection with the Company'sJuly 2015immuno-oncology collaboration with Sanofi, partly offset by the Company's share of higher collaboration losses primarily in connection with commercialization of Praluent.  Collaboration revenue for the full year 2015 and 2014 also included$15 millionand$105 million, respectively, of sales milestone payments from Bayer HealthCare.

Refer to Table 4 for a summary of collaboration revenue.

Research and Development (R&D) Expenses:In 2015, GAAP R&D expenses were$461 millionin the fourth quarter and$1.621 billionfor the full year, compared to$352 millionin the fourth quarter and$1.271 billionfor full year 2014.  The higher 2015 R&D expenses in the fourth quarter and full year were principally due to higher development costs primarily related to dupilumab and higher headcount to support the Company's increased R&D activities.  In 2014, GAAP R&D expenses also included the Company's 50% share, or$34 million, of the cost of purchasing a FDA priority review voucher.  In addition, in 2015, R&D-related non-cash share-based compensation expense was$73 millionfor the fourth quarter and$256 millionfor the full year, compared to$51 millionin the fourth quarter and$184 millionfor the full year 2014.

Selling, General, and Administrative (SG&A) Expenses:In 2015, GAAP SG&A expenses were$295 millionin the fourth quarter and$839 millionfor the full year, compared to$175 millionin the fourth quarter and$519 millionfor full year 2014.  The increases were primarily due to higher headcount and higher commercialization expenses related to EYLEA and Praluent.  These increases were partly offset by a 2014 incremental charge related to the Branded Prescription Drug Fee, based on final regulations issued by the Internal Revenue Service (IRS) in July 2014.  In 2015, SG&A-related non-cash share-based compensation expense was$82 millionfor the fourth quarter and$193 millionfor the full year, compared to$61 millionin the fourth quarter and$135 millionfor the full year 2014.

Cost of Goods Sold (COGS):In 2015, GAAP COGS was$71 millionin the fourth quarter and$242 millionfor the full year, compared to$38 millionin the fourth quarter and$129 millionfor the full year 2014.  COGS primarily consists of royalties as well as costs in connection with producing U.S. EYLEA commercial supplies, and various start-up costs in connection with the Company's Limerick,Irelandcommercial manufacturing facility.  COGS increased principally due to the increase in U.S. EYLEA net product sales, as well as an increase in Limerick start-up costs.

Cost of Collaboration and Contract Manufacturing (COCM):In 2015, GAAP COCM was$40 millionin the fourth quarter and$151 millionfor the full year, compared to$22 millionin the fourth quarter and$76 millionfor the full year 2014.  COCM includes costs the Company incurs in connection with producing commercial drug supplies for Sanofi and Bayer HealthCare.  COCM increased primarily due to royalties payable to Genentech in connection with sales of EYLEA outsidethe United States, as well as the recognition of costs associated with commercial supplies of EYLEA manufactured for Bayer HealthCare.

Other Income (Expense):In 2015 and 2014, GAAP other expense includes losses on extinguishment of debt related to conversions of a portion of the Company's 1.875% convertible senior notes.In addition, GAAP other expense includes interest expense on the Company's convertible senior notes, which decreased due to conversions of a substantial portion of these notes in 2014 and 2015.

Income Tax Expense:In the fourth quarter of 2015, GAAP income tax expense was$72 millionand the effective tax rate was 31.8%, compared to$100 millionand 52.5% in the fourth quarter of 2014.  In 2015, GAAP income tax expense was$589 millionand the effective tax rate was 48.1% for the full year, compared to$423 millionand 55.6% for the full year 2014.  The effective tax rates for the full year of both 2015 and 2014 were negatively impacted, compared to the U.S. federal statutory rate, by losses incurred in foreign jurisdictions with rates lower than the federal statutory rate and the non-tax deductible Branded Prescription Drug Fee, partly offset by the federal tax credit for increased research activities and, in 2015, a higher domestic manufacturing deduction. In the fourth quarter of 2015, the 2015 federal tax credit for increased research activities was enacted retroactive to the beginning of the year.

Non-GAAP and GAAP Net Income:The Company reported non-GAAP net income of$327 million, or$3.15per basic share and$2.83per diluted share, in the fourth quarter of 2015, compared to non-GAAP net income of$328 million, or$3.23per basic share and$2.79per diluted share, in the fourth quarter of 2014.  The Company reported non-GAAP net income of$1.404 billion, or$13.62per basic share and$12.07per diluted share, for the full year 2015, compared to non-GAAP net income of$1.175 billion, or$11.68per basic share and$10.00per diluted share, for the full year 2014.

The Company reported GAAP net income of$155 million, or$1.49per basic share and$1.34per diluted share, in the fourth quarter of 2015, compared to GAAP net income of$90 million, or$0.89per basic share and$0.78per diluted share, in the fourth quarter of 2014.  The Company reported GAAP net income of$636 million, or$6.17per basic share and$5.52per diluted share, for the full year 2015, compared to GAAP net income of$338 million, or$3.36per basic share and$2.98per diluted share, for the full year 2014.

A reconciliation of the Company's GAAP to non-GAAP results is included in Table 3 of this press release.

The Company's full year 2016 financial guidance consists of the following components:

EYLEA U.S. net product sales

Approximately 20% growth over 2015

Non-GAAP unreimbursed R&D(2)

$875 million - $950 million

Non-GAAP SG&A(2)

$925 million - $1,000 million

Cash tax as a % of non-GAAP pre-tax income(2)

35% - 45%*

Capital expenditures

$580 million - $680 million

* - Includes a non-recurring tax payment of approximately $222 million related to the immuno-oncology upfront payment from Sanofi that the Company received in 2015.

(1)

Regeneron records net product sales of EYLEA in the United States.  Outside the United States, EYLEA net product sales comprise sales by Bayer HealthCare in countries other than Japan and sales by Santen Pharmaceutical Co., Ltd. in Japan under a co-promotion agreement with an affiliate of Bayer HealthCare.  The Company recognizes its share of the profits (including a percentage on sales in Japan) from EYLEA sales outside the United States within "Bayer HealthCare collaboration revenue" in its Statements of Operations.

(2)

This press release uses non-GAAP net income, non-GAAP net income per share, non-GAAP unreimbursed R&D, non-GAAP SG&A, and cash tax as a percentage of non-GAAP pre-tax income, which are financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles ("GAAP").  The Company believes that the presentation of these non-GAAP measures is useful to investors because they exclude, as applicable: (i) non-cash share-based compensation expense, which fluctuates from period to period based on factors that are not within the Company's control, such as the Company's stock price on the dates share-based grants are issued; (ii) the incremental charge recorded in the third quarter of 2014 related to the issuance of the final IRS regulations that provide guidance on the annual fee imposed by the Patient Protection and Affordable Care Act (the final IRS regulations differed from the temporary regulations issued in 2011 which resulted in the recognition of a catch-up adjustment); (iii) non-cash interest expense related to the Company's convertible senior notes, since this is not deemed useful in evaluating the Company's operating performance; (iv) loss on extinguishment of debt, since this non-cash charge is based on factors that are not within the Company's control; and (v) income tax expense for 2014, which was principally a non-cash expense due primarily to utilization of net operating loss and tax credit carryforwards, and deductions related to employee stock option exercises.  In 2015, income tax expense adjustments consider the tax effect of reconciling items and an adjustment from GAAP tax expense to the amount of taxes that are paid or payable in cash in respect of the current period.  As there is a significant difference between the Company's effective tax rate and actual cash income taxes paid or payable, GAAP income tax expense is not deemed useful in evaluating the Company's operating performance.  Non-GAAP unreimbursed R&D represents non-GAAP R&D expenses reduced by R&D expense reimbursements from the Company's collaboration partners.  Management uses these non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis.  However, there are limitations in the use of these and other non-GAAP financial measures as they exclude certain expenses that are recurring in nature.  Furthermore, the Company's non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies.  Any non-GAAP financial measure presented by Regeneron should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP.  A reconciliation of the Company's historical GAAP to non-GAAP results is included in Table 3 of this press release.

(3)

The Company's 2016 financial guidance does not assume the completion of any significant business development transactions not completed as of the date of this press release.

(4)

Applicable amounts originally reported for the three months and year ended December 31, 2014 and as of December 31, 2014 have been revised to reflect certain revisions, including a correction to the Company's accounting for certain stock option awards.  These revisions consisted entirely of non-cash adjustments and had no impact on the Company's previously reported non-GAAP financial measures, including non-GAAP net income and non-GAAP net income per share.  Refer to the Company's Form 10-K for the year ended December 31, 2015 (Notes 1 and 14 of the Notes to Consolidated Financial Statements) for further details.

Regeneron will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2015 financial and operating results onTuesday, February 9, 2016, at8:30 AM.  To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International).  A link to the webcast may be accessed from the "Events and Presentations" page of Regeneron's website atwww.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.

Regeneron is a leading science-based biopharmaceutical company based inTarrytown, New Yorkthat discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron commercializes medicines for high LDL-cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases.  For additional information about the Company, please visitwww.regeneron.comor follow @Regeneron on Twitter.

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements.  Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned; the likelihood and timing of achieving any of the anticipated milestones described in this new release; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products, including without limitation Praluent®(alirocumab) Injection, sarilumab, dupilumab, fasinumab and REGN2222; ongoing regulatory obligations and oversight impacting Regeneron's marketed products (such as EYLEA®(aflibercept) Injection and Praluent), research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), on the commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance, including without limitation those relating to EYLEA U.S. net product sales, non-GAAP unreimbursed R&D, non-GAAP SG&A, cash tax as a percentage of non-GAAP pre-tax income, and capital expenditures; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare LLC, to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the fiscal year endedDecember 31, 2014and its Form 10-Q for the quarterly period endedSeptember 30, 2015.  Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

This press release and/or the financial results attached to this press release include amounts that are considered "non-GAAP financial measures" under SEC rules.  As required, Regeneron has provided reconciliations of historical non-GAAP financial measures.

TABLE 1

Assets:

Cash and marketable securities

$

1,677,385

$

1,360,634

Accounts receivable - trade, net

1,152,489

739,379

Accounts receivable from Sanofi and Bayer HealthCare

315,304

236,993

Inventories

238,578

128,861

Deferred tax assets

461,945

315,416

Property, plant, and equipment, net

1,594,120

974,309

Other assets

169,311

82,080

Total assets

$

5,609,132

$

3,837,672

Liabilities and stockholders' equity:

Accounts payable, accrued expenses, and other liabilities

$

760,619

$

619,083

Deferred revenue

818,166

209,274

Facility lease obligations

364,708

312,291

Convertible senior notes

10,802

146,773

Stockholders' equity

3,654,837

2,550,251

Total liabilities and stockholders' equity

$

5,609,132

$

3,837,672

* Certain revisions have been made to the amounts originally reported as of December 31, 2014.  See note (4) above.

TABLE 2

Revenues:

Net product sales

$

749,524

$

521,518

$

2,689,478

$

1,750,762

Sanofi collaboration revenue

165,672

135,271

758,873

541,299

Bayer HealthCare collaboration revenue

164,809

137,095

580,488

495,555

Other revenue

18,072

8,445

74,889

31,941

1,098,077

802,329

4,103,728

2,819,557

Expenses:

Research and development

461,210

351,745

1,620,577

1,271,353

Selling, general, and administrative

294,954

175,307

838,526

519,267

Cost of goods sold

71,078

37,957

241,702

129,030

Cost of collaboration and contract manufacturing

39,753

21,517

151,007

75,988

866,995

586,526

2,851,812

1,995,638

Income from operations

231,082

215,803

1,251,916

823,919

Other income (expense):

Investment and other income (expense)

1,750

2,952

6,283

8,157

Interest expense

(3,609)

(6,350)

(14,241)

(37,372)

Loss on extinguishment of debt

(1,934)

(22,682)

(18,861)

(33,469)

(3,793)

(26,080)

(26,819)

(62,684)

Income before income taxes

227,289

189,723

1,225,097

761,235

Income tax expense

(72,295)

(99,628)

(589,041)

(423,109)

Net income

$

154,994

$

90,095

$

636,056

$

338,126

Net income per share - basic

$

1.49

$

0.89

$

6.17

$

3.36

Net income per share - diluted

$

1.34

$

0.78

$

5.52

$

2.98

Weighted average shares outstanding - basic

103,765

101,467

103,061

100,612

Weighted average shares outstanding - diluted

115,496

114,246

115,230

113,413

* Certain revisions have been made to the amounts originally reported for the three months and year ended December 31, 2014.  See note (4) above.

TABLE 3

GAAP net income

$

154,994

$

90,095

$

636,056

$

338,126

Adjustments:

R&D: Non-cash share-based compensation expense

72,570

51,180

255,708

184,347

SG&A: Non-cash share-based compensation expense

82,212

61,095

193,026

134,715

SG&A: Branded Prescription Drug Fee incremental charge

—

—

—

40,600

COGS and COCM: Non-cash share-based compensation expense

3,609

744

10,315

2,688

Interest expense: Non-cash interest related to convertible senior notes

41

2,375

2,818

17,821

Other expense: Loss on extinguishment of debt

1,934

22,682

18,861

33,469

Non-cash income taxes

11,433

99,628

287,110

423,109

Non-GAAP net income

$

326,793

$

327,799

$

1,403,894

$

1,174,875

Non-GAAP net income per share - basic

$

3.15

$

3.23

$

13.62

$

11.68

Non-GAAP net income per share - diluted(a)

$

2.83

$

2.79

$

12.07

$

10.00

Shares used in calculating:

Non-GAAP net income per share - basic

103,765

101,467

103,061

100,612

Non-GAAP net income per share - diluted(b)

115,639

117,825

116,355

117,966

* Certain revisions have been made to the amounts originally reported for the three months and year ended December 31, 2014.  See note (4) above.

(a)

For diluted non-GAAP net income per share calculation, excludes $5.0 million of interest expense for the year ended December 31, 2014 related to the contractual coupon interest rate on the Company's 1.875% convertible senior notes, since these securities were dilutive.  Such amounts were not material for the three months ended December 31, 2015 and 2014, and for the year ended December 31, 2015.

(b)

Weighted average shares outstanding includes the dilutive effect, if any, of employee stock options, restricted stock awards, convertible senior notes, and warrants.

TABLE 4

Sanofi collaboration revenue:

Regeneron's share of losses in connection with commercialization of antibodies

$

(96,459)

$

(24,253)

$

(240,042)

$

(41,378)

Reimbursement of Regeneron research and development expenses

171,366

143,664

776,086

552,567

Reimbursement of Regeneron commercialization-related expenses

68,205

12,417

157,350

19,480

Other

22,560

3,443

65,479

10,630

Total Sanofi collaboration revenue

165,672

135,271

758,873

541,299

Bayer HealthCare collaboration revenue:

Regeneron's net profit in connection with commercialization of EYLEA outside the United States

140,100

88,011

466,667

301,302

Sales milestones

—

30,000

15,000

105,000

Cost-sharing of Regeneron development expenses

3,326

(1,661)

18,962

26,231

Other

21,383

20,745

79,859

63,022

Total Bayer HealthCare collaboration revenue

164,809

137,095

580,488

495,555

Total collaboration revenue

$

330,481

$

272,366

$

1,339,361

$

1,036,854